Finance entity
Of the tracked stories, 1 of 2 also mention Citi, the most common co-covered peer. Across a 13-day span, the pace is roughly 1.1 stories per week. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention Citi, the most common co-covered peer. Across a 13-day span, the pace is roughly 1.1 stories per week. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Their average consequence score of 6 runs below the beat's 6.3 for that window. They are better corroborated than the beat average, carrying 3 original sources each against 2.6 for the same window. Teladoc Health appears in 2 tracked Finance stories published from February 26, 2026 through March 10, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 900 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Teladoc Health. Shared-story counts are live from our verified record — not editorial picks.
Product Transition
Hims & Hers expected to fully phase out compounded GLP-1s in favor of branded Ozempic.
Strategic Settlement
Hims & Hers and Novo Nordisk announce a distribution partnership and lawsuit dismissal.
Market Surge
HIMS stock skyrockets 41% with record-breaking trading volume.
Market Rally
TDOC, NOW, and ENOV all trade significantly higher as investors digest earnings data.
Teladoc 8-K Filing
Teladoc discloses results of operations, showing significant margin improvement.
ServiceNow Earnings
ServiceNow reports strong Q4 results, sparking a multi-week rally in SaaS stocks.
Legal Friction
Novo Nordisk files patent infringement lawsuits against telehealth providers selling compounded GLP-1s.
Hims & Hers Health shares skyrocketed following a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The agreement shifts the telehealth provider's weight-loss strategy from controversial compounded versions to FDA-approved Ozempic, significantly de-risking its long-term growth profile.
Teladoc Health shares surged following its latest financial results, while ServiceNow and Enovis also posted significant gains amid positive market sentiment. The movements highlight a robust period for healthcare technology and enterprise software as companies demonstrate resilient growth and operational efficiency.
Teladoc Health is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
